Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma (NCT04078230)
🩺 Plain-English Summary (8th-Grade Level)
Intrahepatic cholangiocarcinoma (ICC) is one of the common malignant tumors. Lymph node metastasis is an important factor affecting the poor prognosis of intrahepatic cholangiocarcinoma. The eighth edition of the AJCC guidelines recommends at least 6 lymph nodes to be used for staging. The American Hepatobiliary and Pancreatic Association also recommends the removal of hilar lymph nodes as part of the radical surgery for intrahepatic cholangiocarcinoma. However, some scholars have found that patients with regional lymph nodes have similar survival rates. This contradictory result has prompted more scholars to conduct clinical research to explore the necessity and standardization of lymph node dissection in intrahepatic cholangiocarcinoma.
Who can join: Review the eligibility criteria below.
Location: The Johns Hopkins Hospital — Baltimore, Maryland
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
- Extend LymphAdenectomy (PROCEDURE)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- The Johns Hopkins Hospital — Baltimore, Maryland
- China-Japan Friendship Hospital — Beijing, Beijing Municipality
- Chinese PLA General Hospital — Beijing, Beijing Municipality
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University — Guangzhou, Guangdong
- Hunan Provincial People's Hospital — Changsha, Hunan
- The Affiliated Hospital of Inner Mongolia Medical University — Hohhot, Inner Mongolia
- Renji Hospital Affiliated to Shanghai Jiao Tong University — Shanghai, Shanghai Municipality
- Xinhua Hospital Affiliated to Shanghai Jiao Tong University — Shanghai, Shanghai Municipality
- Zhong Shan Hospital Fudan University — Shanghai, Shanghai Municipality
- The First Affiliated Hospital of Xi 'an Jiaotong University — Xi’an, Shanxi
- West China Hospital Sichuan University — Chengdu, Sichuan
- The Second Affiliated Hospital Zhejiang University School of Medicine — Hanzhou, Zhejiang
- Zhejiang cancer hospital — Hanzhou, Zhejiang
📞 Contact the Study Coordinator
Phone: 86-15906686716
Email: zjulijiangtao@163.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Intrahepatic Cholangiocarcinoma
- Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma — Madison, Wisconsin
- A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement — Birmingham, Alabama
- Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery — Bethesda, Maryland
- The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer — Fairfax, Virginia
- Liver Transplantation in Intrahepatic Cholangiocarcinoma — Newark, New Jersey
Explore by condition: All Intrahepatic Cholangiocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.